Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/60922
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Branford, S. | - |
dc.contributor.author | Seymour, J. | - |
dc.contributor.author | Grigg, A. | - |
dc.contributor.author | Arthur, C. | - |
dc.contributor.author | Rudzki, Z. | - |
dc.contributor.author | Lynch, K. | - |
dc.contributor.author | Hughes, T. | - |
dc.date.issued | 2007 | - |
dc.identifier.citation | Clinical Cancer Research, 2007; 13(23):7080-7085 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.issn | 1557-3265 | - |
dc.identifier.uri | http://hdl.handle.net/2440/60922 | - |
dc.description.abstract | Purpose: In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL. Experimental Design: BCR-ABL levels were measured in a subset of 53 imatinib-treated IRIS trial patients for up to 7 years (29 first-line, 24 second-line). Levels were deemed undetectable using strict PCR sensitivity criteria. Results: By 18 months, the majority achieved a 3-log reduction [major molecular response (MMR)]. BCR-ABL continued to decline but at a slower rate (median time to 4-log reduction and undetectable BCR-ABL of 45 and 66 months for first-line). The probability of undetectable BCR-ABL increased considerably from 36 to 81 months of first-line imatinib {7% [95% confidence interval (95% CI), 0-17%] versus 52% (95% CI, 32-72%)}. Undetectable BCR-ABL was achieved in 18 of 53 patients and none of these 18 lost MMR after a median follow-up of 33 months. Conversely, MMR was lost in 6 of 22 (27%) patients with sustained detectable BCR-ABL and was associated with BCR-ABL mutations in 3 of 6. Loss of MMR was recently defined as suboptimal imatinib response. There was no difference in the probability of achieving molecular responses between first- and second-line patients but first-line had a significantly higher probability of maintaining MMR [P = 0.03; 96% (95% CI, 88-100%) versus 71% (95% CI, 48-93%)]. Conclusions: With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR-ABL was no longer a rare event. Loss of MMR was only observed in patients with sustained detectable BCR-ABL. | - |
dc.description.statementofresponsibility | Susan Branford, John F. Seymour, Andrew Grigg, Chris Arthur, Zbigniew Rudzki, Kevin Lynch and Timothy Hughes | - |
dc.language.iso | en | - |
dc.publisher | Amer Assoc Cancer Research | - |
dc.rights | © 2007 American Association for Cancer Research. | - |
dc.source.uri | http://dx.doi.org/10.1158/1078-0432.ccr-07-0844 | - |
dc.subject | chronic myeloid leukemia | - |
dc.subject | imatinib | - |
dc.subject | BCR-ABL | - |
dc.subject | major molecular response | - |
dc.subject | real-time quantitative PCR | - |
dc.title | BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-07-0844 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Branford, S. [0000-0002-1964-3626] [0000-0002-5095-7981] | - |
dc.identifier.orcid | Hughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509] | - |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.